HCV
  • Featured content
    Led by Norah Terrault, MD, MPH, a panel of experts including Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; and Ira M. Jacobson, MD, provides an overview of the current state of HCV therapy, emphasizing the unprecedented levels of efficacy and simplicity in curing individual patients, and discusses important strategies for eliminating HCV infection across communities and ultimately throughout the world.
  • Featured content
    In this downloadable slideset, Sherilyn C. Brinkley, MSN, CRNP; Jordan J. Feld, MD, MPH; Jason Grebely, BSc, PhD; Nancy Reau, MD, FAASLD, AGAF; and Phoebe Sebhatu, PharmD, BCPS, review best practices in addressing practical aspects of managing patients with HCV, including interpretation of current guidelines and payer policies, approaches to patient education and engagement in care, specialty pharmacy utilization and navigation of the insurance appeals process, and management of drug users and patients who become reinfected.
    Date Posted: 11/28/2016
  • Featured content
    Listen to this downloadable audio from a live Webinar in which an expert faculty member discusses the clinical impact of new data reported at the Barcelona meeting.
    Date Posted: 6/1/2016
  • Featured content
    In this downloadable slideset, Ira M. Jacobson, MD, reviews the newest regimens and data for genotype 1 HCV infection.
    Date Posted: 6/1/2016
  • Featured content
    In this Interactive Case Challenge, Paul Y. Kwo, MD, explores important considerations when selecting all-oral HCV therapy for patients with cirrhosis.
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 342 Shown
  • Hepatitis C Update for Primary Care

    In this downloadable slideset tailored for primary care clinicians, Terry D. Box, MD, reviews age-based and risk-based HCV screening, optimal treatment and counseling strategies for HCV-infected patients, and the parameters that warrant referral to specialist care.
    Date Posted: 2/21/2017
  • Learning Module cme-icon ce-icon

    Clinical Impact of New Data From Boston 2016

    In this Expert Analysis, Ira M. Jacobson, MD, and Stefan Zeuzem, MD, provide expert interpretation of the most clinically important new data on HCV, HBV, and NASH from this important annual conference.
    Faculty: Ira M. Jacobson MD, Stefan Zeuzem MD
    Released: 2/1/2017
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017 1 comment / Last Comment: 2/13/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
  • Addressing Practical Challenges in HCV Management

    In this on-demand multimedia module combining slides and audio from a live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts, multidisciplinary expert faulty provide their perspectives on practical aspects of managing patients with HCV, including interpretation of current guidelines and payer policies, approaches to patient engagement in care, specialty pharmacy utilization and navigation of the insurance appeals process, and management of people who inject drugs.
    Date Posted: 12/20/2016
  • Video Module cme-icon ce-icon

    HCV: Continuing Advances From Individual Cure to Disease Elimination

    Led by Norah Terrault, MD, MPH, a panel of experts including Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; and Ira M. Jacobson, MD, provides an overview of the current state of HCV therapy, emphasizing the unprecedented levels of efficacy and simplicity in curing individual patients, and discusses important strategies for eliminating HCV infection across communities and ultimately throughout the world.
    Faculty: Gregory Dore MBBS, PhD, FRACP, MPH, Graham R. Foster FRCP, PhD, Ira M. Jacobson MD
    Released: 12/19/2016
  • HCV: Continuing Advances From Individual Cure to Disease Elimination

    In this downloadable slideset, Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; Ira M. Jacobson, MD; and Norah Terrault, MD, MPH, review strategies for eliminating HCV infection, both at the individual level and at the population level. The slideset includes a review of where the HCV field now stands, from the unprecedented levels of efficacy and simplicity in curing individual patients, through to the steps required to advance toward the goal of eradicating HCV across communities and ultimately throughout the world.
    Date Posted: 12/7/2016
  • Clinical Impact of New Data From Boston 2016

    In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
    Date Posted: 11/30/2016
  • Addressing Practical Challenges in HCV Management

    In this downloadable slideset, Sherilyn C. Brinkley, MSN, CRNP; Jordan J. Feld, MD, MPH; Jason Grebely, BSc, PhD; Nancy Reau, MD, FAASLD, AGAF; and Phoebe Sebhatu, PharmD, BCPS, review best practices in addressing practical aspects of managing patients with HCV, including interpretation of current guidelines and payer policies, approaches to patient education and engagement in care, specialty pharmacy utilization and navigation of the insurance appeals process, and management of drug users and patients who become reinfected.
    Date Posted: 11/28/2016
  • Key Studies Influencing My Practice Following Boston 2016

    Listen to a rapid review of the key hepatology studies from Boston 2016 expected to affect clinical practice, followed by expert answers to participants’ questions.
    Date Posted: 11/28/2016
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016 1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
10 of 342 Shown
Show 10 More
Loading...